The status of modeled claims

Abstract

The only acceptable modeled claims for costs and outcomes are those that are testable and can be validated in a timeframe that is acceptable to a formulary committee. This issue provides four papers which explore the methodological issues in validation, the UK experience with NICE, the questions a formulary committee should ask of modeled claims, and the role of Big Data in validating modeled claims.

Keywords::

• Modeled claims
• Credibility
• Feedback

Transparency

Declaration of funding

This paper has received no funding.

Declaration of financial/other relationships

None reported. JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.